TRANSFUSION OF ALLOGENIC CORD BLOOD TO PATIENTS WITH MULTIPLE MYELOMA: SAFETY ANALYSIS AND INFLUENCE ON THE IMMUNOPHENOTYPE OF BLOOD LYMPHOCYTES IN THE EARLY PERIOD
- Authors: Tyumina O.1,2, Davydkin I.L.3, Limareva L.V.3, Chibashova A.V.3, Gusarova E.A.3, Sokolova V.V.3, Bogush V.V.3, Tyumin I.V.4, Gritsenko T.A.3, Trusova L.M.5
-
Affiliations:
- State Budgetary Institution of Health Care "Samara Regional Medical Center Dynasty»
- Samara State Medical University of the Ministry of Health of Russia, Samara, Russian Federation
- FSBEI HE SamSMU MOH
- MRRC them. A.F. Tsyba - branch of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia
- Samara Regional Medical Center Dynasty
- Section: Joint Immunology Forum 2024
- URL: https://rusimmun.ru/jour/article/view/16866
- DOI: https://doi.org/10.46235/1028-7221-16866-TOA
- ID: 16866
Cite item
Full Text
Abstract
Severe immune dysfunction occurs in the majority of cancer patients. One of the methods for overcoming immune disorders is transplantation of peripheral blood hematopoietic stem cells, both autologous and allogeneic, and transfusion of allogeneic natural killer cells (NK cells). Umbilical cord blood is a known source of not only hematopoietic stem cells (HSCs) but also NK cells, characterized by the rapid availability of blood samples from public cord blood banks. Purpose of the study: to analyze the safety of simultaneous transfusion of three allogeneic cord blood to patients with relapsed/refractory multiple myeloma in the early period - 7 days after administration, and also to study the response of subpopulations of peripheral blood lymphocytes of patients to this intervention. Material and methods: The pilot study included 10 patients (7 men and 3 women) with relapsed/refractory multiple myeloma who had previously received more than 3 lines of therapy. The age of the patients was 59.4+3.4 years; all of them received a single transfusion of three allogeneic samples of umbilical cord blood with an average dose of leukocytes of 60.50+8.2x108 (NK cells - 4.36+1.2x108) per one patient. A total of 30 samples of umbilical cord blood, alloreactive for KIR receptors of the receptor-ligand type, were transfused. The selection of HSCs concentrates was carried out in the umbilical cord blood bank of the Dynasty Medical Center. Before transfusion of umbilical cord blood, patients received cyclophosphamide 5 mg/kg. After transfusion, patients received five subcutaneous injections of IL-2 (roncoleukin) in the amount of 1 million units per day. Observation at the time of assessment of preliminary results - 7 days after transfusion. Analysis of the immunophenotype of patients' lymphocytes was studied twice: on the day of transfusion before the start of the protocol and 7 days after transfusion of umbilical cord blood. Results: No early adverse reactions to transfusions were observed. Conclusion. Simultaneous transfusion of three allogeneic cord blood to patients with relapsed/refractory multiple myeloma is a safe procedure, there are no adverse reactions or serious adverse events, as well as significant reactions and changes in the immunophenotype of patients' lymphocytes in the early observation period within 7 days after the intervention.
About the authors
Olga Tyumina
State Budgetary Institution of Health Care "Samara Regional Medical Center Dynasty»;Samara State Medical University of the Ministry of Health of Russia, Samara, Russian Federation
Author for correspondence.
Email: centr123@bk.ru
ORCID iD: 0000-0003-4962-6998
Phd, medical director State Budgetary Institution of Health Care "Samara Regional Medical Center Dynasty»,
Russian Federation, 443 095, Russia, Samara, str. Tashkentskay 159Igor Leonidovich Davydkin
FSBEI HE SamSMU MOH
Email: i.l.davydkin@samsmu.ru
ORCID iD: 0000-0002-4318-4247
the head of the Chair of Hospital Therapy with Courses of Polyclinic Therapy and Transfusiology, M.D.,PhD, professor
Russian Federation, 443099, Russia, Samara, Chapaevskay 89Larisa Vladimirovna Limareva
FSBEI HE SamSMU MOH
Email: l.v.limareva@samsmu.ru
ORCID iD: 0000-0003-4529-5896
Doctor of Biological Sciences,Professor of the Department of General and Clinical Microbiology
Russian Federation, 443099, Russia, Samara, str.Chapaevskay 89Anzhelika Vladimirovna Chibashova
FSBEI HE SamSMU MOH
Email: a.v.antipova@samsmu.ru
ORCID iD: 0000-0003-2851-7995
assistant at the Department of Hospital Therapy with a course of outpatient therapy and transfusiology
Russian Federation, 443099, Russia, Samara, str.Chapaevskay 89Elizaveta Alekseevna Gusarova
FSBEI HE SamSMU MOH
Email: gusarova@bk.ru
ORCID iD: 0009-0004-2072-1646
student
Russian Federation, 443099, Russia, Samara, str.Chapaevskay 89Valeria Vladislavovna Sokolova
FSBEI HE SamSMU MOH
Email: sokolova@bk.ru
ORCID iD: 0009-0006-3096-8487
student
Russian Federation, 443099, Russia, Samara, str.Chapaevskay 89Vanda Vitalievna Bogush
FSBEI HE SamSMU MOH
Email: v.v.bogush@samsmu.ru
biologist of the clinical diagnostic laboratory of the clinics
Russian Federation, 443099, Rssia, Samara, str.Chapaevskay 89Ivan Valeriavich Tyumin
MRRC them. A.F. Tsyba - branch of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia
Email: inbio@bk.ru
ORCID iD: 0000-0002-7053-9285
postgraduate student of the Department of Clinical Immunology
Russian Federation, 249036, Russia,Obninsk,str.Koroleva 4Taras Alekseevich Gritsenko
FSBEI HE SamSMU MOH
Email: taras876@mail.ru
ORCID iD: 0000-0002-2794-5122
PhD, Deputy Director of the Research Institute of Hematology,transfusiology and intensive care
Russian Federation, 443099, Russia, Samara, str. Chapaevskya 89Larisa Michailovna Trusova
Samara Regional Medical Center Dynasty
Email: trusova@cordbank.ru
ORCID iD: 0000-0001-8602-3905
Head of department of Immunologi
Russian Federation, 443095, Russia, Samara, str. Tachlentskya 159